Clinical trial

MDMA-Assisted Psychotherapy for Treatment Resistant PTSD in Adolescents

University of California, Los AngelesWithdrawnPhase 2Started Jul 1, 20250 enrolledUnited StatesNCT06353282

Abstract

The primary objective of this study is to determine the safety and feasibility of 3,4-methylenedioxymethamphetamine (MDMA) -assisted psychotherapy to treat resistant post-traumatic stress disorder (PTSD). The secondary objectives are the exploration of effectiveness for treatment-resistant PTSD, symptoms of depression, and anxiety symptoms.

Topics & conditions

Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.

MDMAPTSD

Keywords

AdolescentPsychotherapyPTSD, Post Traumatic Stress DisorderAdolescentsPsychotherapy

View on registry

Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.

Related research

ArticleMDMA

Aesthetic mediation and lateral agency: Rethinking trauma and drug consumption in 'crisis ordinariness'.

Fomiatti R, Keane H, Nourse G +4

Europe PMC2026

ArticlePsilocybin

Australia to prescribe MDMA and psilocybin for PTSD and depression in world first.

Haridy R

Europe PMC2023

PreprintMDMA

The Brinzei MDMA-PTSD Protocol: Addressing the Food and Drug Administration’s Breaking Blind Concerns with Precision Approaches to Post-Traumatic Stress Disorder Treatment

Brinzei O

Europe PMC2025